Skip to main content
SpringerLink
Log in

Lymphoblastic Lymphoma

  • Chapter
  • First Online:
Non-Hodgkin's Lymphoma in Childhood and Adolescence

Abstract

Lymphoblastic lymphoma (LBL) is the second most common type of non-Hodgkin lymphoma (NHL) in childhood and adolescence accounting for 25–35% of all cases. The majority, 70–80%, is of T-lymphoblastic origin, and 20–25% arise from B-lymphoblasts. With intensification of therapy in the last decades, the event-free and overall survivals for pediatric LBL patients are now exceeding 80%, but the burden of therapy causes considerable morbidity and late sequela. In addition, the prognosis of relapsed patients remains poor (Schmidt and Burkhardt. Pediatr Hematol Oncol. 30:484–508, 2013). This chapter will focus on the pathogenesis and biology of LBL, recent advances in the therapy of LBL, and ongoing and future efforts in optimizing therapy and developing novel targeted treatment approaches.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 84.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Hardcover Book
USD 109.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Schmidt E, Burkhardt B. Lymphoblastic lymphoma in childhood and adolescence. Pediatr Hematol Oncol. 2013;30(6):484–508.

    Article  CAS  PubMed  Google Scholar 

  2. Termuhlen AM, Smith LM, Perkins SL, Lones M, Finlay JL, Weinstein H, et al. Disseminated lymphoblastic lymphoma in children and adolescents: results of the COG A5971 trial: a report from the Children’s Oncology Group. Br J Haematol. 2013;162(6):792–801.

    Article  CAS  PubMed  Google Scholar 

  3. Landmann E, Burkhardt B, Zimmermann M, Meyer U, Woessmann W, Klapper W, et al. Results and conclusions of the European Intergroup EURO-LB02 trial in children and adolescents with lymphoblastic lymphoma. Haematologica. 2017;102(12):2086–96.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  4. Burkhardt B, Zimmermann M, Oschlies I, Niggli F, Mann G, Parwaresch R, et al. The impact of age and gender on biology, clinical features and treatment outcome of non-Hodgkin lymphoma in childhood and adolescence. Br J Haematol. 2005;131(1):39–49.

    Article  PubMed  Google Scholar 

  5. Oschlies I, Burkhardt B, Salaverria I, Rosenwald A, d’Amore ES, Szczepanowski M, et al. Clinical, pathological and genetic features of primary mediastinal large B-cell lymphomas and mediastinal gray zone lymphomas in children. Haematologica. 2011;96(2):262–8.

    Article  PubMed  Google Scholar 

  6. Patel JL, Smith LM, Anderson J, Abromowitch M, Campana D, Jacobsen J, et al. The immunophenotype of T-lymphoblastic lymphoma in children and adolescents: a Children’s Oncology Group report. Br J Haematol. 2012;159(4):454–61.

    Article  PubMed  PubMed Central  Google Scholar 

  7. Ducassou S, Ferlay C, Bergeron C, Girard S, Laureys G, Pacquement H, et al. Clinical presentation, evolution, and prognosis of precursor B-cell lymphoblastic lymphoma in trials LMT96, EORTC 58881, and EORTC 58951. Br J Haematol. 2011;152(4):441–51.

    Article  CAS  PubMed  Google Scholar 

  8. Neth O, Seidemann K, Jansen P, Mann G, Tiemann M, Ludwig WD, et al. Precursor B-cell lymphoblastic lymphoma in childhood and adolescence: clinical features, treatment, and results in trials NHL-BFM 86 and 90. Med Pediatr Oncol. 2000;35(1):20–7.

    Article  CAS  PubMed  Google Scholar 

  9. Bene MC, Castoldi G, Knapp W, Ludwig WD, Matutes E, Orfao A, et al. Proposals for the immunological classification of acute leukemias. European Group for the Immunological Characterization of Leukemias (EGIL). Leukemia. 1995;9(10):1783–6.

    CAS  PubMed  Google Scholar 

  10. Bene MC, Nebe T, Bettelheim P, Buldini B, Bumbea H, Kern W, et al. Immunophenotyping of acute leukemia and lymphoproliferative disorders: a consensus proposal of the European LeukemiaNet Work Package 10. Leukemia. 2011;25(4):567–74.

    Article  CAS  PubMed  Google Scholar 

  11. Borowitz MJC, J KC, Downing JR, Le Beau MM, Arber DA. Precursor lymphoid neoplasms. In: Swerdlow SH, Campo E, Harris NL, Jaffe ES, Plieri SA, Stein H, Thiele J, editors. WHO classification of tumours of haematopoietic and lymphoid tissue. Lyon: International Agency for Research on Cancer (IARC); 2017. p. 200–13.

    Google Scholar 

  12. Dworzak MN, Buldini B, Gaipa G, Ratei R, Hrusak O, Luria D, et al. AIEOP-BFM consensus guidelines 2016 for flow cytometric immunophenotyping of Pediatric acute lymphoblastic leukemia. Cytometry B Clin Cytom. 2018;94(1):82–93.

    Article  PubMed  Google Scholar 

  13. Roberts KG, Mullighan CG. Genomics in acute lymphoblastic leukaemia: insights and treatment implications. Nat Rev Clin Oncol. 2015;12(6):344–57.

    Article  CAS  PubMed  Google Scholar 

  14. Burkhardt B. Paediatric lymphoblastic T-cell leukaemia and lymphoma: one or two diseases? Br J Haematol. 2010;149(5):653–68.

    Article  CAS  PubMed  Google Scholar 

  15. Basso K, Mussolin L, Lettieri A, Brahmachary M, Lim WK, Califano A, et al. T-cell lymphoblastic lymphoma shows differences and similarities with T-cell acute lymphoblastic leukemia by genomic and gene expression analyses. Genes Chromosomes Cancer. 2011;50(12):1063–75.

    Article  CAS  PubMed  Google Scholar 

  16. Uyttebroeck A, Vanhentenrijk V, Hagemeijer A, Boeckx N, Renard M, Wlodarska I, et al. Is there a difference in childhood T-cell acute lymphoblastic leukaemia and T-cell lymphoblastic lymphoma? Leuk Lymphoma. 2007;48(9):1745–54.

    Article  PubMed  Google Scholar 

  17. Oschlies I, Burkhardt B, Chassagne-Clement C, d’Amore ES, Hansson U, Hebeda K, et al. Diagnosis and immunophenotype of 188 pediatric lymphoblastic lymphomas treated within a randomized prospective trial: experiences and preliminary recommendations from the European childhood lymphoma pathology panel. Am J Surg Pathol. 2011;35(6):836–44.

    Article  PubMed  Google Scholar 

  18. Smock KJ, Nelson M, Tripp SR, Sanger WG, Abromowitch M, Cairo MS, et al. Characterization of childhood precursor T-lymphoblastic lymphoma by immunophenotyping and fluorescent in situ hybridization: a report from the Children’s Oncology Group. Pediatr Blood Cancer. 2008;51(4):489–94.

    Article  PubMed  PubMed Central  Google Scholar 

  19. Coustan-Smith E, Mullighan CG, Onciu M, Behm FG, Raimondi SC, Pei D, et al. Early T-cell precursor leukaemia: a subtype of very high-risk acute lymphoblastic leukaemia. Lancet Oncol. 2009;10(2):147–56.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  20. Zhang J, Ding L, Holmfeldt L, Wu G, Heatley SL, Payne-Turner D, et al. The genetic basis of early T-cell precursor acute lymphoblastic leukaemia. Nature. 2012;481(7380):157–63.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  21. You MJ, Medeiros LJ, Hsi ED. T-lymphoblastic leukemia/lymphoma. Am J Clin Pathol. 2015;144(3):411–22.

    Article  CAS  PubMed  Google Scholar 

  22. Haydu JE, Ferrando AA. Early T-cell precursor acute lymphoblastic leukaemia. Curr Opin Hematol. 2013;20(4):369–73.

    Article  CAS  PubMed  Google Scholar 

  23. Patrick K, Wade R, Goulden N, Mitchell C, Moorman AV, Rowntree C, et al. Outcome for children and young people with Early T-cell precursor acute lymphoblastic leukaemia treated on a contemporary protocol, UKALL 2003. Br J Haematol. 2014;166(3):421–4.

    Article  CAS  PubMed  Google Scholar 

  24. Swerdlow SH, Campo E, Harris NL, Jaffe E, Pileri S, Stein H, et al., editors. WHO classification of tumours of haematopoietic and lymphoid tissue. Lyon: IARC; 2008.

    Google Scholar 

  25. Matutes E, Pickl WF, Van’t Veer M, Morilla R, Swansbury J, Strobl H, et al. Mixed-phenotype acute leukemia: clinical and laboratory features and outcome in 100 patients defined according to the WHO 2008 classification. Blood. 2011;117(11):3163–71.

    Article  CAS  PubMed  Google Scholar 

  26. Boddu P, Yin CC, Kanagal-Shamanna R, Tang G, Thakral B, Kadia T, et al. An Unsuspected Finding of t(9;22): a rare case of Philadelphia chromosome-positive b-lymphoblastic lymphoma. Case Rep Hematol. 2017;2017:2413587.

    PubMed  PubMed Central  Google Scholar 

  27. Ahlmann M, Meyer C, Marschalek R, Burkhardt B, Koehler G, Klapper W, et al. Complex MLL rearrangement in non-infiltrated bone marrow in an infant with stage II precursor B-lymphoblastic lymphoma. Eur J Haematol. 2014;93(4):349–53.

    Article  CAS  PubMed  Google Scholar 

  28. Maitra A, McKenna RW, Weinberg AG, Schneider NR, Kroft SH. Precursor B-cell lymphoblastic lymphoma. A study of nine cases lacking blood and bone marrow involvement and review of the literature. Am J Clin Pathol. 2001;115(6):868–75.

    Article  CAS  PubMed  Google Scholar 

  29. Geethakumari PR, Hoffmann MS, Pemmaraju N, Hu S, Jorgensen JL, O’Brien S, et al. Extramedullary B lymphoblastic leukemia/lymphoma (B-ALL/B-LBL): a diagnostic challenge. Clin Lymphoma Myeloma Leuk. 2014;14(4):e115–8.

    Article  PubMed  PubMed Central  Google Scholar 

  30. Meyer JA, Zhou D, Mason CC, Downie JM, Rodic V, Abromowitch M, et al. Genomic characterization of pediatric B-lymphoblastic lymphoma and B-lymphoblastic leukemia using formalin-fixed tissues. Pediatr Blood Cancer. 2017;64(7) https://doi.org/10.1002/pbc.26363.

    Article  CAS  Google Scholar 

  31. Burkhardt B, Bruch J, Zimmermann M, Strauch K, Parwaresch R, Ludwig WD, et al. Loss of heterozygosity on chromosome 6q14-q24 is associated with poor outcome in children and adolescents with T-cell lymphoblastic lymphoma. Leukemia. 2006;20(8):1422–9.

    Article  CAS  PubMed  Google Scholar 

  32. Lones MA, Heerema NA, Le Beau MM, Sposto R, Perkins SL, Kadin ME, et al. Chromosome abnormalities in advanced stage lymphoblastic lymphoma of children and adolescents: a report from CCG-E08. Cancer GenetCytogenet. 2007;172(1):1–11.

    Article  CAS  Google Scholar 

  33. Breit S, Stanulla M, Flohr T, Schrappe M, Ludwig WD, Tolle G, et al. Activating NOTCH1 mutations predict favorable early treatment response and long term outcome in child-hood precursor T-cell lymphoblastic leukemia. Blood. 2006;108(4):1151–7.

    Article  CAS  PubMed  Google Scholar 

  34. Kox C, Zimmermann M, Stanulla M, Leible S, Schrappe M, Ludwig WD, et al. The favorable effect of activating NOTCH1 receptor mutations on long-term outcome in T-ALL patients treated on the ALL-BFM 2000 protocol can be separated from FBXW7 loss of function. Leukemia. 2010;24(12):2005–13.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  35. Bonn BR, Rohde M, Zimmermann M, Krieger D, Oschlies I, Niggli F, et al. Incidence and prognostic relevance of genetic variations in T-cell lymphoblastic lymphoma in childhood and adolescence. Blood. 2013;121(16):3153–60.

    Article  CAS  PubMed  Google Scholar 

  36. Callens C, Baleydier F, Lengline E, Ben Abdelali R, Petit A, Villarese P, et al. Clinical impact of NOTCH1 and/or FBXW7 mutations, FLASH deletion, and TCR status in pediatric T-cell lymphoblastic lymphoma. J Clin Oncol. 2012;30(16):1966–73.

    Article  CAS  PubMed  Google Scholar 

  37. Park MJ, Taki T, Oda M, Watanabe T, Yumura-Yagi K, Kobayashi R, et al. FBXW7 and NOTCH1 mutations in childhood T cell acute lymphoblastic leukaemia and T cell non-Hodgkin lymphoma. Br J Haematol. 2009;145(2):198–206.

    Article  CAS  PubMed  Google Scholar 

  38. Baleydier F, Decouvelaere AV, Bergeron J, Gaulard P, Canioni D, Bertrand Y, et al. T cell receptor genotyping and HOXA/TLX1 expression define three T lymphoblastic lymphoma subsets which might affect clinical outcome. Clin Cancer Res. 2008;14(3):692–700.

    Article  CAS  PubMed  Google Scholar 

  39. Burkhardt B, Moericke A, Klapper W, Greene F, Salzburg J, Damm-Welk C, et al. Pediatric precursor T lymphoblastic leukemia and lymphoblastic lymphoma: differences in the common regions with loss of heterozygosity at chromosome 6q and their prognostic impact. LeukLymphoma. 2008;49(3):451–61.

    CAS  Google Scholar 

  40. Balbach ST, Makarova O, Bonn BR, Zimmermann M, Rohde M, Oschlies I, et al. Proposal of a genetic classifier for risk group stratification in pediatric T-cell lymphoblastic lymphoma reveals differences from adult T-cell lymphoblastic leukemia. Leukemia. 2016;30(4):970–3.

    Article  CAS  PubMed  Google Scholar 

  41. Song MS, Salmena L, Pandolfi PP. The functions and regulation of the PTEN tumour suppressor. Nat Rev Mol Cell Biol. 2012;13(5):283–96.

    Article  CAS  PubMed  Google Scholar 

  42. Hales EC, Taub JW, Matherly LH. New insights into Notch1 regulation of the PI3K-AKT-mTOR1 signaling axis: targeted therapy of gamma-secretase inhibitor resistant T-cell acute lymphoblastic leukemia. Cell Signal. 2014;26(1):149–61.

    Article  CAS  PubMed  Google Scholar 

  43. Bandapalli OR, Zimmermann M, Kox C, Stanulla M, Schrappe M, Ludwig WD, et al. NOTCH1 activation clinically antagonizes the unfavorable effect of PTEN inactivation in BFM-treated children with precursor T-cell acute lymphoblastic leukemia. Haematologica. 2013;98(6):928–36.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  44. Paganin M, Grillo MF, Silvestri D, Scapinello G, Buldini B, Cazzaniga G, et al. The presence of mutated and deleted PTEN is associated with an increased risk of relapse in childhood T cell acute lymphoblastic leukaemia treated with AIEOP-BFM ALL protocols. Br J Haematol. 2018;182(5):705–11.

    Article  CAS  PubMed  Google Scholar 

  45. Zuurbier L, Homminga I, Calvert V, te Winkel ML, Buijs-Gladdines JG, Kooi C, et al. NOTCH1 and/or FBXW7 mutations predict for initial good prednisone response but not for improved outcome in pediatric T-cell acute lymphoblastic leukemia patients treated on DCOG or COALL protocols. Leukemia. 2010;24(12):2014–22.

    Article  CAS  PubMed  Google Scholar 

  46. Gutierrez A, Dahlberg SE, Neuberg DS, Zhang J, Grebliunaite R, Sanda T, et al. Absence of biallelic TCRgamma deletion predicts early treatment failure in pediatric T-cell acute lymphoblastic leukemia. J Clin Oncol. 2010;28(24):3816–23.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  47. Yang YL, Hsiao CC, Chen HY, Lin KH, Jou ST, Chen JS, et al. Absence of biallelic TCRgamma deletion predicts induction failure and poorer outcomes in childhood T-cell acute lymphoblastic leukemia. Pediatr Blood Cancer. 2012;58(6):846–51.

    Article  PubMed  Google Scholar 

  48. Pomari E, Lovisa F, Carraro E, Primerano S, D’Amore ESG, Bonvini P, et al. Clinical impact of miR-223 expression in pediatric T-Cell lymphoblastic lymphoma. Oncotarget. 2017;8(64):107886–98.

    Article  PubMed  PubMed Central  Google Scholar 

  49. Burkhardt B, Mueller S, Khanam T, Perkins SL. Current status and future directions of T-lymphoblastic lymphoma in children and adolescents. Br J Haematol. 2016;173(4):545–59.

    Article  PubMed  Google Scholar 

  50. Tubergen DG, Krailo MD, Meadows AT, Rosenstock J, Kadin M, Morse M, et al. Comparison of treatment regimens for pediatric lymphoblastic non-Hodgkin’s lymphoma: a Childrens Cancer Group study. J Clin Oncol. 1995;13(6):1368–76.

    Article  CAS  PubMed  Google Scholar 

  51. Burkhardt B, Oschlies I, Klapper W, Zimmermann M, Woessmann W, Meinhardt A, et al. Non-Hodgkin’s lymphoma in adolescents: experiences in 378 adolescent NHL patients treated according to pediatric NHL-BFM protocols. Leukemia. 2011;25(1):153–60.

    Article  CAS  PubMed  Google Scholar 

  52. Uyttebroeck A, Suciu S, Laureys G, Robert A, Pacquement H, Ferster A, et al. Treatment of childhood T-cell lymphoblastic lymphoma according to the strategy for acute lymphoblastic leukaemia, without radiotherapy: long term results of the EORTC CLG 58881 trial. Eur J Cancer. 2008;44(6):840–6.

    Article  PubMed  Google Scholar 

  53. Termuhlen AM, Smith LM, Perkins SL, Lones M, Finlay JL, Weinstein H, et al. Outcome of newly diagnosed children and adolescents with localized lymphoblastic lymphoma treated on Children’s Oncology Group trial A5971: a report from the Children’s Oncology Group. Pediatr Blood Cancer. 2012;59(7):1229–33.

    Article  PubMed  Google Scholar 

  54. Stark B, Avigad S, Luria D, Manor S, Reshef-Ronen T, Avrahami G, et al. Bone marrow minimal disseminated disease (MDD) and minimal residual disease (MRD) in childhood T-cell lymphoblastic lymphoma stage III, detected by flow cytometry (FC) and real-time quantitative polymerase chain reaction (RQ-PCR). Pediatr Blood Cancer. 2009;52(1):20–5.

    Article  PubMed  Google Scholar 

  55. Coustan-Smith E, Sandlund JT, Perkins SL, Chen H, Chang M, Abromowitch M, et al. Minimal disseminated disease in childhood T-cell lymphoblastic lymphoma: a report from the children’s oncology group. J Clin Oncol. 2009;27(21):3533–9.

    Article  PubMed  PubMed Central  Google Scholar 

  56. Mussolin L, Buldini B, Lovisa F, Carraro E, Disaro S, Nigro LL, et al. Detection and role of minimal disseminated disease in children with lymphoblastic lymphoma: the AIEOP experience. Pediatr Blood Cancer. 2015;62(11):1906–13.

    Article  PubMed  Google Scholar 

  57. Bardi E, Csoka M, Garai I, Szegedi I, Muller J, Gyorke T, et al. Value of FDG-PET/CT examinations in different cancers of children, focusing on lymphomas. Pathol Oncol Res. 2014;20(1):139–43.

    Article  CAS  PubMed  Google Scholar 

  58. Nakatani K, Nakamoto Y, Watanabe K, Saga T, Higashi T, Togashi K. Roles and limitations of FDG PET in pediatric non-Hodgkin lymphoma. Clin Nucl Med. 2012;37(7):656–62.

    Article  PubMed  Google Scholar 

  59. Riad R, Omar W, Kotb M, Hafez M, Sidhom I, Zamzam M, et al. Role of PET/CT in malignant pediatric lymphoma. Eur J Nucl Med Mol Imaging. 2010;37(2):319–29.

    Article  PubMed  Google Scholar 

  60. Riad R, Omar W, Sidhom I, Zamzam M, Zaky I, Hafez M, et al. False-positive F-18 FDG uptake in PET/CT studies in pediatric patients with abdominal Burkitt’s lymphoma. Nucl Med Commun. 2010;31(3):232–8.

    Article  PubMed  Google Scholar 

  61. Sioka C. The utility of FDG PET in diagnosis and follow-up of lymphoma in childhood. Eur J Pediatr. 2013;172(6):733–8.

    Article  PubMed  Google Scholar 

  62. Murphy SB. Classification, staging and end results of treatment of childhood non-Hodgkin’s lymphomas: dissimilarities from lymphomas in adults. Semin Oncol. 1980;7(3):332–9.

    CAS  PubMed  Google Scholar 

  63. Rosolen A, Perkins SL, Pinkerton CR, Guillerman RP, Sandlund JT, Patte C, et al. Revised International Pediatric Non-Hodgkin Lymphoma Staging System. J Clin Oncol. 2015;33(18):2112–8.

    Article  PubMed  PubMed Central  Google Scholar 

  64. Wollner N, Burchenal JH, Lieberman PH, Exelby P, D’Angio G, Murphy ML. Non-Hodgkin’s lymphoma in children. A comparative study of two modalities of therapy. Cancer. 1976;37(1):123–34.

    Article  CAS  PubMed  Google Scholar 

  65. Wollner N, Exelby PR, Lieberman PH. Non-Hodgkin’s lymphoma in children: a progress report on the original patients treated with the LSA2-L2 protocol. Cancer. 1979;44(6):1990–9.

    Article  CAS  PubMed  Google Scholar 

  66. Reiter A, Schrappe M, Parwaresch R, Henze G, Muller-Weihrich S, Sauter S, et al. Non-Hodgkin’s lymphomas of childhood and adolescence: results of a treatment stratified for biologic subtypes and stage--a report of the Berlin-Frankfurt-Munster Group. J Clin Oncol. 1995;13(2):359–72.

    Article  CAS  PubMed  Google Scholar 

  67. Reiter A, Schrappe M, Ludwig WD, Tiemann M, Parwaresch R, Zimmermann M, et al. Intensive ALL-type therapy without local radiotherapy provides a 90% event-free survival for children with T-cell lymphoblastic lymphoma: a BFM group report. Blood. 2000;95(2):416–21.

    CAS  PubMed  Google Scholar 

  68. Jin L, Zhang R, Huang S, Yang J, Duan YL, Zhang YH. Clinical features and prognosis of children with lymphoblastic lymphoma. Zhonghua Zhong Liu Za Zhi. 2012;34(2):138–42.

    PubMed  Google Scholar 

  69. Kobayashi R, Takimoto T, Nakazawa A, Fujita N, Akazai A, Yamato K, et al. Inferior outcomes of stage III T lymphoblastic lymphoma relative to stage IV lymphoma and T-acute lymphoblastic leukemia: long-term comparison of outcomes in the JACLS NHL T-98 and ALL T-97 protocols. Int J Hematol. 2014;99(6):743–9.

    Article  CAS  PubMed  Google Scholar 

  70. Sun XF, Xia ZJ, Zhen ZJ, Xiang XJ, Xia Y, Ling JY, et al. Intensive chemotherapy improved treatment outcome for Chinese children and adolescents with lymphoblastic lymphoma. Int J Clin Oncol. 2008;13(5):436–41.

    Article  CAS  PubMed  Google Scholar 

  71. Gao YJ, Pan C, Tang JY, Lu FJ, Chen J, Xue HL, et al. Clinical outcome of childhood lymphoblastic lymphoma in Shanghai China 2001-2010. Pediatr Blood Cancer. 2014;61(4):659–63.

    Article  PubMed  Google Scholar 

  72. Sunami S, Sekimizu M, Takimoto T, Mori T, Mitsui T, Fukano R, et al. Prognostic impact of intensified maintenance therapy on children with advanced lymphoblastic lymphoma: a report from the Japanese Pediatric Leukemia/Lymphoma Study Group ALB-NHL03 study. Pediatr Blood Cancer. 2016;63(3):451–7.

    Article  PubMed  Google Scholar 

  73. Patte C, Kalifa C, Flamant F, Hartmann O, Brugieres L, Valteau-Couanet D, et al. Results of the LMT81 protocol, a modified LSA2L2 protocol with high dose methotrexate, on 84 children with non-B-cell (lymphoblastic) lymphoma. Med Pediatr Oncol. 1992;20(2):105–13.

    Article  CAS  PubMed  Google Scholar 

  74. Asselin BL, Devidas M, Wang C, Pullen J, Borowitz MJ, Hutchison R, et al. Effectiveness of high-dose methotrexate in T-cell lymphoblastic leukemia and advanced-stage lymphoblastic lymphoma: a randomized study by the Children’s Oncology Group (POG 9404). Blood. 2011;118(4):874–83.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  75. Sterba J, Kovacs G, Matus M, Bubanska E, Kyr M, Krenova Z, et al. Capizzi methotrexate with BFM backbone without craniospinal irradiation is effective treatment for pediatric lymphoblastic lymphoma: results from 5 countries with I-BFM LL 09 protocol. Br J Haematol. 2015;171(Suppl. 1):33.

    Google Scholar 

  76. Winter SS, Dunsmore KP, Devidas M, Wood BL, Esiashvili N, Chen Z, et al. Improved survival for children and young adults with T-lineage acute lymphoblastic leukemia: results from the Children’s Oncology Group AALL0434 methotrexate randomization. J Clin Oncol. 2018;36(29):2926–34. https://doi.org/10.1200/JCO.2018.77.7250.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  77. Dunsmore KP, Winter S, Devidas M, Wood BL, Esiashvili N, Eisenberg N, Briegel N, Hayashi RJ, Gastier-Foster JM, Carroll AJ, Heerema N, Asselin B, Rabin KR, Zweidler-McKay P, Raetz RA, Loh ML, Winick NJ, Carroll WL, Hunger S. COG AALL0434: a randomized trial testing nelarabine in newly diagnosed t-cell malignancy. J Clin Oncol. 2018;36:10500.

    Article  Google Scholar 

  78. Mitsui T, Mori T, Fujita N, Inada H, Horibe K, Tsurusawa M. Retrospective analysis of relapsed or primary refractory childhood lymphoblastic lymphoma in Japan. Pediatr Blood Cancer. 2009;52:591.

    Article  PubMed  Google Scholar 

  79. Gross TG, Hale GA, He W, Camitta BM, Sanders JE, Cairo MS, et al. Hematopoietic stem cell transplantation for refractory or recurrent non-Hodgkin lymphoma in children and adolescents. Biol Blood Marrow Transplant. 2009;16(2):223–30.

    Article  PubMed  PubMed Central  Google Scholar 

  80. Burkhardt B, Zimmermann M, Oschlies I, Klapper W, Meinhardt A, Landmann E, et al., editors. Outcome of adolescents with non-Hodgkin lymphoma in the BFM studies: relevance of gender and histological subtype. In: 3rd international symposium on childhood, adolescent and young adult non-Hodgkin’s Lymphoma, Frankfurt: Hematology meeting reports; June 2009.

    Google Scholar 

  81. Cohen MH, Johnson JR, Justice R, Pazdur R. FDA drug approval summary: nelarabine (Arranon) for the treatment of T-cell lymphoblastic leukemia/lymphoma. Oncologist. 2008;13(6):709–14.

    Article  CAS  PubMed  Google Scholar 

  82. Raetz EA, Teachey DT. T-cell acute lymphoblastic leukemia. Hematology Am Soc Hematol Educ Program. 2016;2016(1):580–8.

    Article  PubMed  PubMed Central  Google Scholar 

  83. Delgado-Martin C, Meyer LK, Huang BJ, Shimano KA, Zinter MS, Nguyen JV, et al. JAK/STAT pathway inhibition overcomes IL7-induced glucocorticoid resistance in a subset of human T-cell acute lymphoblastic leukemias. Leukemia. 2017;31(12):2568–76.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  84. Bride KL, Vincent TL, Im SY, Aplenc R, Barrett DM, Carroll WL, et al. Preclinical efficacy of daratumumab in T-cell acute lymphoblastic leukemia. Blood. 2018;131(9):995–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  85. De Smedt R, Peirs S, Morscio J, Matthijssens F, Roels J, Reunes L, et al. Preclinical evaluation of second generation PIM inhibitors for the treatment of T-cell acute lymphoblastic leukemia and lymphoma. Haematologica. 2019;104(1):e17–20.

    Article  PubMed  PubMed Central  Google Scholar 

  86. Amylon MD, Shuster J, Pullen J, Berard C, Link MP, Wharam M, et al. Intensive high-dose asparaginase consolidation improves survival for pediatric patients with T cell acute lymphoblastic leukemia and advanced stage lymphoblastic lymphoma: a Pediatric Oncology Group study. Leukemia. 1999;13(3):335–42.

    Article  CAS  PubMed  Google Scholar 

  87. Burkhardt B, Woessmann W, Zimmermann M, Kontny U, Vormoor J, Doerffel W, et al. Impact of cranial radiotherapy on central nervous system prophylaxis in children and adolescents with central nervous system-negative stage III or IV lymphoblastic lymphoma. J Clin Oncol. 2006;24(3):491–9.

    Article  PubMed  Google Scholar 

  88. Abromowitch M, Sposto R, Perkins S, Zwick D, Siegel S, Finlay J, et al. Shortened intensified multi-agent chemotherapy and non-cross resistant maintenance therapy for advanced lymphoblastic lymphoma in children and adolescents: report from the Children’s Oncology Group. Br J Haematol. 2008;143(2):261–7.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  89. Abromowitch M, Termuhlen A, Chang M, Perkins S, Gross T, Weinstein H, et al. High-dose methotrexate and early intensification of therapy do not improve 3 year EFS in children and adolescents with disseminated lymphoblastic lymphoma. Results of the randomized arms of COG A5971. Blood. 2008;12:Abstract No. 3610.

    Google Scholar 

  90. Pillon M, Piglione M, Garaventa A, Conter V, Giuliano M, Arcamone G, et al. Long-term results of AIEOP LNH-92 protocol for the treatment of pediatric lymphoblastic lymphoma: a report of the Italian Association of pediatric hematology and oncology. Pediatr Blood Cancer. 2009;53(6):953–9.

    Article  PubMed  Google Scholar 

  91. Sandlund JT, Pui CH, Zhou Y, Behm FG, Onciu M, Razzouk BI, et al. Effective treatment of advanced-stage childhood lymphoblastic lymphoma without prophylactic cranial irradiation: results of St Jude NHL13 study. Leukemia. 2009;23(6):1127–30.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  92. Uyttebroeck A, Suciu S, Plat G, Laureys G, Costa V, Rohrlich P, et al. Dexamethasone (DEX) versus prednisone (PRED) in T-cell non Hodgkin lymphoma (T-NHL): results of the randomized phase III trial 58951 of the EORTC Children Leukemia Group. Br J Haematol. 2012;159(Suppl. 1):37.

    Google Scholar 

  93. Bergeron C, Coze C, Segura C, Pacquement H, Gandemer V, Ducassou S, et al. Treatment of childhood T-cell lymphoblastic lymphoma-long-term results of the SFOP LMT96 trial. Pediatr Blood Cancer. 2015;62(12):2150–6.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Pediatric Hematology and Oncology, University Hospital Münster, Münster, Germany

    Birgit Burkhardt

  2. Division of Oncology, Center for Cancer and Blood Disorders, Children’s National Medical Center, The George Washington University School of Medicine, Washington, DC, USA

    Birte Wistinghausen

Authors
  1. Birgit Burkhardt
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Birte Wistinghausen
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Birte Wistinghausen .

Editor information

Editors and Affiliations

  1. University of Toronto, The Hospital for Sick Children, Toronto, ON, Canada

    Oussama Abla

  2. Medical University of Vienna, St. Anna Children’s Hospital, Vienna, Wein, Austria

    Andishe Attarbaschi

Rights and permissions

Reprints and permissions

Copyright information

© 2019 Springer Nature Switzerland AG

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Burkhardt, B., Wistinghausen, B. (2019). Lymphoblastic Lymphoma. In: Abla, O., Attarbaschi, A. (eds) Non-Hodgkin's Lymphoma in Childhood and Adolescence. Springer, Cham. https://doi.org/10.1007/978-3-030-11769-6_12

Download citation

  • DOI: https://doi.org/10.1007/978-3-030-11769-6_12

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-030-11768-9

  • Online ISBN: 978-3-030-11769-6

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation